Kemp-Harper Barbara
Department of Pharmacology, Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia .
J Cardiovasc Pharmacol. 2021 Dec 1;78(Suppl 6):S13-S18. doi: 10.1097/FJC.0000000000001151.
Nitroxyl (HNO), the 1 electron-reduced and protonated form of nitric oxide (NO•), has emerged as a nitrogen oxide with a suite of vasoprotective properties and therapeutic advantages over its redox sibling. Although HNO has garnered much attention due to its cardioprotective actions in heart failure, its ability to modulate vascular function, without the limitations of tolerance development and NO• resistance, is desirable in the treatment of vascular disease. HNO serves as a potent vasodilator and antiaggregatory agent and has an ability to limit vascular inflammation and reactive oxygen species generation. In addition, its resistance to scavenging by reactive oxygen species and ability to target distinct vascular signaling pathways (Kv, KATP, and calcitonin gene-related peptide) contribute to its preserved efficacy in hypertension, diabetes, and hypercholesterolemia. In this review, the vasoprotective actions of HNO will be compared with those of NO•, and the therapeutic utility of HNO donors in the treatment of angina, acute cardiovascular emergencies, and chronic vascular disease are discussed.
硝酰(HNO)是一氧化氮(NO•)单电子还原并质子化的形式,已成为一种氮氧化物,具有一系列血管保护特性,与其氧化还原同类物相比具有治疗优势。尽管HNO因其在心力衰竭中的心脏保护作用而备受关注,但在治疗血管疾病时,其调节血管功能的能力不受耐受性发展和NO•抵抗的限制,这是很理想的。HNO是一种强效血管舒张剂和抗聚集剂,能够限制血管炎症和活性氧的产生。此外,它对活性氧清除的抗性以及靶向不同血管信号通路(Kv、KATP和降钙素基因相关肽)的能力,有助于其在高血压、糖尿病和高胆固醇血症中保持疗效。在这篇综述中,将比较HNO与NO•的血管保护作用,并讨论HNO供体在治疗心绞痛、急性心血管急症和慢性血管疾病中的治疗效用。